192 related articles for article (PubMed ID: 26739488)
21. Chronic Exposure to TNFα Impairs Secretion of Glucagon-Like Peptide-1.
Gagnon J; Sauvé M; Zhao W; Stacey HM; Wiber SC; Bolz SS; Brubaker PL
Endocrinology; 2015 Nov; 156(11):3950-60. PubMed ID: 26270730
[TBL] [Abstract][Full Text] [Related]
22. Endogenous islet uncoupling protein-2 expression and loss of glucose homeostasis in ob/ob mice.
Saleh MC; Wheeler MB; Chan CB
J Endocrinol; 2006 Sep; 190(3):659-67. PubMed ID: 17003267
[TBL] [Abstract][Full Text] [Related]
23. Incretin hormones: Their role in health and disease.
Nauck MA; Meier JJ
Diabetes Obes Metab; 2018 Feb; 20 Suppl 1():5-21. PubMed ID: 29364588
[TBL] [Abstract][Full Text] [Related]
24. Glucose-dependent insulinotropic polypeptide: effects on insulin and glucagon secretion in humans.
Christensen MB
Dan Med J; 2016 Apr; 63(4):. PubMed ID: 27034187
[TBL] [Abstract][Full Text] [Related]
25. Activation of sodium-glucose cotransporter 1 ameliorates hyperglycemia by mediating incretin secretion in mice.
Moriya R; Shirakura T; Ito J; Mashiko S; Seo T
Am J Physiol Endocrinol Metab; 2009 Dec; 297(6):E1358-65. PubMed ID: 19808907
[TBL] [Abstract][Full Text] [Related]
26. Brain glucagon-like peptide 1 signaling controls the onset of high-fat diet-induced insulin resistance and reduces energy expenditure.
Knauf C; Cani PD; Ait-Belgnaoui A; Benani A; Dray C; Cabou C; Colom A; Uldry M; Rastrelli S; Sabatier E; Godet N; Waget A; Pénicaud L; Valet P; Burcelin R
Endocrinology; 2008 Oct; 149(10):4768-77. PubMed ID: 18556349
[TBL] [Abstract][Full Text] [Related]
27. The entero-insular axis: implications for human metabolism.
Ranganath LR
Clin Chem Lab Med; 2008; 46(1):43-56. PubMed ID: 18020966
[TBL] [Abstract][Full Text] [Related]
28. beta-cell failure in diabetes and preservation by clinical treatment.
Wajchenberg BL
Endocr Rev; 2007 Apr; 28(2):187-218. PubMed ID: 17353295
[TBL] [Abstract][Full Text] [Related]
29. GLP-1 contributes to increases in PGC-1α expression by downregulating miR-23a to reduce apoptosis.
Wang C; Li Q; Wang W; Guo L; Guo C; Sun Y; Zhang J
Biochem Biophys Res Commun; 2015 Oct; 466(1):33-9. PubMed ID: 26315270
[TBL] [Abstract][Full Text] [Related]
30. Insulin detemir enhances proglucagon gene expression in the intestinal L cells via stimulating β-catenin and CREB activities.
Liu S; Liu R; Chiang YT; Song L; Li X; Jin T; Wang Q
Am J Physiol Endocrinol Metab; 2012 Sep; 303(6):E740-51. PubMed ID: 22811470
[TBL] [Abstract][Full Text] [Related]
31. Evidence for paracrine/autocrine regulation of GLP-1-producing cells.
Kappe C; Zhang Q; Holst JJ; Nyström T; Sjöholm A
Am J Physiol Cell Physiol; 2013 Nov; 305(10):C1041-9. PubMed ID: 23986202
[TBL] [Abstract][Full Text] [Related]
32. The incretin notion and its relevance to diabetes.
Habener JF
Endocrinol Metab Clin North Am; 1993 Dec; 22(4):775-94. PubMed ID: 8125072
[TBL] [Abstract][Full Text] [Related]
33. [The physiology of glucagon-like peptide-1 and its role in the pathophysiology of type 2 diabetes mellitus].
Escalada FJ
Med Clin (Barc); 2014 Sep; 143 Suppl 2():2-7. PubMed ID: 25437458
[TBL] [Abstract][Full Text] [Related]
34. UCP2 mRNA expression is dependent on glucose metabolism in pancreatic islets.
Dalgaard LT
Biochem Biophys Res Commun; 2012 Jan; 417(1):495-500. PubMed ID: 22177951
[TBL] [Abstract][Full Text] [Related]
35. Diabetes and obesity treatment based on dual incretin receptor activation: 'twincretins'.
Skow MA; Bergmann NC; Knop FK
Diabetes Obes Metab; 2016 Sep; 18(9):847-54. PubMed ID: 27160961
[TBL] [Abstract][Full Text] [Related]
36. Genetic determinants of circulating GIP and GLP-1 concentrations.
Almgren P; Lindqvist A; Krus U; Hakaste L; Ottosson-Laakso E; Asplund O; Sonestedt E; Prasad RB; Laurila E; Orho-Melander M; Melander O; Tuomi T; Holst JJ; Nilsson PM; Wierup N; Groop L; Ahlqvist E
JCI Insight; 2017 Nov; 2(21):. PubMed ID: 29093273
[TBL] [Abstract][Full Text] [Related]
37. [Incretin hormones in the treatment of type 2 diabetes. Part I: influence of insulinotropic gut-derived hormones (incretins) on glucose metabolism].
Matuszek B; Lenart-Lipińska M; Nowakowski A
Endokrynol Pol; 2007; 58(6):522-8. PubMed ID: 18205109
[TBL] [Abstract][Full Text] [Related]
38. Role of GLP-1 induced glucagon suppression in type 2 diabetes mellitus.
Hare KJ
Dan Med Bull; 2010 Sep; 57(9):B4181. PubMed ID: 20816021
[TBL] [Abstract][Full Text] [Related]
39. Incretin dysfunction in type 2 diabetes: clinical impact and future perspectives.
Ahrén B
Diabetes Metab; 2013 May; 39(3):195-201. PubMed ID: 23643349
[TBL] [Abstract][Full Text] [Related]
40. Glucagon-like peptide-1 improves beta-cell antioxidant capacity via extracellular regulated kinases pathway and Nrf2 translocation.
Fernández-Millán E; Martín MA; Goya L; Lizárraga-Mollinedo E; Escrivá F; Ramos S; Álvarez C
Free Radic Biol Med; 2016 Jun; 95():16-26. PubMed ID: 26968794
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
